DFTX
Definium Therapeutics, Inc.
Key Financials
Net Income
$-183793000
↓ 69.1%
Total Liabilities
$107.8M
↑ 77.5%
Total Assets
$440.1M
↑ 45.7%
Operating Income
$-166309000
↓ 60.0%
EPS (Diluted)
$-2.06
↓ 33.8%
Cash & Equivalents
$257.8M
↓ 5.8%
Shareholders' Equity
$332.3M
↑ 37.6%
Operating Cash Flow
$-131560000.00
↓ 66.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/29/2026 | View on SEC |
| 4 | 9/29/2026 | View on SEC |
| 4 | 9/29/2026 | View on SEC |
| 4 | 9/29/2026 | View on SEC |
| 4 | 9/29/2026 | View on SEC |
| 144 | 9/25/2026 | View on SEC |
| 144 | 9/25/2026 | View on SEC |
| 144 | 9/25/2026 | View on SEC |
| 144 | 9/25/2026 | View on SEC |
| 144 | 9/25/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DFTX |
| Company Name | Definium Therapeutics, Inc. |
| CIK | 1813814 |
| Sector | Medicinal Chemicals & Botanical Products |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2833 |
| SIC Description | Medicinal Chemicals & Botanical Products |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | A1 |
| Phone | 212-220-6633 |